Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 37,400

Document Document Title
WO/2019/029620A1
Provided is a compound of formula I with an ATX inhibitory activity and the application thereof in preparing drugs for treating ATX related diseases.  
WO/2019/029561A1
A process method for synthesizing 1,5,7-triazabicyclo[5.5.0]dec-5-ene (TBD) in an autocatalytic amphipathic mixed solvent. In the process method in the present invention, di(3-amino propyl)amine and guanidine hydrochloride are used as ra...  
WO/2019/029541A1
Provided are a fibroblast growth factor receptor (FGFR) irreversible inhibitor as represented by formula I, a pharmaceutically acceptable salt, a stereoisomer thereof, and pharmaceutical preparations, pharmaceutical compositions and uses...  
WO/2019/029507A1
A preparation method for imidazoisoindole derivatives. Specifically provided is a preparation method for imidazoisoindole derivatives represented by a formula (I). The method comprises: dissolving a compound represented by a formula (II)...  
WO/2019/029663A1
A 1H-pyrazolo[4,3-H]quinazoline compound represented by formula (I) can be used for treating cell proliferation dysfunction, and is an broad-spectrum and strongly-active inhibitor for a cell cyclin-dependent kinase (CDK).  
WO/2019/024908A1
Substituted penta- and hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a preparation method therefor, a drug combination that...  
WO/2019/027765A1
Disclosed are new small molecules having a substituted pyrimidine or substituted fused pyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising t...  
WO/2019/023786A1
Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are ...  
WO/2019/023799A1
Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided...  
WO/2019/027960A1
The invention provides compounds of formula (I) or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides cry...  
WO/2019/028309A1
Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II). (Formulae (...  
WO/2019/027163A1
Disclosed are: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode; and an electro...  
WO/2019/027860A1
The present invention relates to compounds of (II) and an acceptable salt or hydrate thereof method of making same.  
WO/2019/026883A1
The present invention relates to a method for producing a macrocyclic compound, the method comprising a step for reacting an aldehyde represented by formula (3) and a pyrrole ring compound represented by formula (4) to obtain a macrocycl...  
WO/2019/027054A1
The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the co...  
WO/2019/028250A1
Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation....  
WO/2019/020070A1
The present invention relates to a piperazine heteroaryl derivative, a preparation method therefor and the use of same in medicine. In particular, the present invention relates to the piperazine heteroaryl derivative as shown in the gene...  
WO/2019/021208A1
The invention is directed to substituted indazole derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states (I) wherein R1...  
WO/2019/020987A1
The present invention relates to compounds which are of use in the field of agriculture as herbicides. The compounds in question are of formula II and comprise a spirofused tricycle core: wherein R4 and R5 together with the carbon atom t...  
WO/2019/021059A1
The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hea...  
WO/2019/020102A1
The present invention relates to a method for preparing a pyrimidone heteroaryl derivative and an intermediate of the pyrimidone heteroaryl derivative. Specifically, in the present invention, the pyrimidone heteroaryl derivative is prepa...  
WO/2019/022435A1
Disclosed are: a compound represented by chemical formula 1; an organic electronic device comprising a first electrode, a second electrode and an organic layer between the first electrode and the second electrode; and an electronic appar...  
WO/2019/020790A1
The present invention relates to a method for preparing 3-[(3S)-7- bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-IH-[l,4]-benzodiaze pin-3-yl] propionic acid methyl ester from (2-amino-5-bromo-phenyl)-pyridin-2- yl-methanone. The present inve...  
WO/2019/019532A1
Disclosed are a leveling agent, a metal plating composition containing same, and a preparation method therefor and the use thereof. The raw materials of the metal electroplating composition comprise a metal plating solution and a levelin...  
WO/2019/023165A1
The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.  
WO/2019/019959A1
Provided are crystal forms X, III, and V of a monosuccinate of ribociclib as a compound shown in formula (I) and preparation methods thereof. Also provided are pharmaceutical compositions containing the crystal forms. Also provided are u...  
WO/2019/020508A1
The present invention relates to a novel process with low environmental impact for the synthesis of rucaparib with high yield and purity, which comprises a regioselective coupling reaction between an indole and an iodo-aryl, performed in...  
WO/2019/022061A1
This fungicide for agricultural and horticultural use includes a compound represented by formula (I) (in the formula, X represents a halogen group, etc.; n represents any integer of 0-4; when n is 2 or higher, X may be the same or differ...  
WO/2019/015608A1
Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as s...  
WO/2019/016397A1
The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.  
WO/2019/017633A1
The specification relates to a compound represented by chemical formula 1 and to an organic light emitting device comprising the same.  
WO/2019/015561A1
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a,...  
WO/2019/017314A1
Provided is a new polycyclic aromatic hydrocarbon derivative. The present invention provides a derivative of a polycyclic aromatic hydrocarbon having six or more aromatic rings, wherein the polycyclic aromatic hydrocarbon derivative incl...  
WO/2019/012033A1
The present invention relates to deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl- 3-(3methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydio-[1,2,4]tri zolo[4,3-a]pyrazin-7(8H)- yl)methanone, or a pharmaceutically acceptable salt or solvat...  
WO/2019/011316A1
The present invention relates to a crystalline form of a BTK kinase inhibitor and a preparation method therefor. In particular, the present invention relates to a type II crystal of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(2,6-difl...  
WO/2019/011715A1
The present invention relates to substituted pyrazolo-quinazoline derivatives which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline me...  
WO/2019/012093A1
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or ch...  
WO/2019/014194A1
The present invention provides a method for preparing a colour-stable preparation of a magnesium chlorophyllin alkali metal salt or alkali earth metal salt from natural sources of chlorophyll. The invention further provides a colour-stab...  
WO/2019/011217A1
Provided are pyrrolo[1,2-b]pyridazine compounds or pharmacologically acceptable salts thereof and use thereof. The pyrrolo[1,2-b]pyridazine compounds or pharmacologically acceptable salts thereof have inhibitory effects on poly(ADP-ribos...  
WO/2019/012284A1
The present invention relates to pyrrolopyrimidine compounds according to Formula (I) and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological d...  
WO/2019/012063A1
The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.  
WO/2019/011287A1
The present invention relates to a preparation method for an imidazoisoindole derivative. In particular, the present invention relates to a preparation method for an imidazoisoindole derivative as shown in formula I, comprising the step ...  
WO/2019/011166A1
The invention relates to a macrocyclic amide compound containing a thiophene group, and a preparation method of the macrocyclic amide compound and an intermediate thereof. The invention also relates to the macrocyclic amide compound cont...  
WO/2019/011802A1
The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.  
WO/2019/011228A1
The present invention provides an imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compound. In particular, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt or prodrug thereof: (I), A and R1-R...  
WO/2019/007003A1
The present invention discloses a pyrazolo[3,4-d]pyrimidine derivative as shown by formula (I). The compound provided by the present invention has a significant effect on inhibiting growth of tumor cells, can be used for preventing and/o...  
WO/2019/007866A1
The invention relates to a composition comprising an electron-transporting host and a hole transporting host, to the use thereof in electronic devices and electronic devices containing said composition. The electron-transporting host is ...  
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2019/007578A1
Object of the present invention is an efficient process for the preparation of the active pharmaceutical ingredient Sitagliptine and the 2,4,5-trifluorophenylacetic acid (TFAA) and salt thereof, which is a key intermediate for the synthe...  
WO/2019/008126A1
Crystalline form II of Compound A. HC1: (Formula) characterised by its X-ray powder diffraction diagram and solid-state 13C NMR spectrum, and pharmaceutical compositions containing it.  

Matches 1 - 50 out of 37,400